BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 26954482)

  • 1. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
    Catalá-López F; Macías Saint-Gerons D; González-Bermejo D; Rosano GM; Davis BR; Ridao M; Zaragoza A; Montero-Corominas D; Tobías A; de la Fuente-Honrubia C; Tabarés-Seisdedos R; Hutton B
    PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
    Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
    Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
    Wang K; Hu J; Luo T; Wang Y; Yang S; Qing H; Cheng Q; Li Q
    Kidney Blood Press Res; 2018; 43(3):768-779. PubMed ID: 29794446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.
    Saglimbene V; Palmer SC; Ruospo M; Natale P; Maione A; Nicolucci A; Vecchio M; Tognoni G; Craig JC; Pellegrini F; Lucisano G; Hegbrant J; Ariano R; Lamacchia O; Sasso A; Morano S; Filardi T; De Cosmo S; Pugliese G; Procaccini DA; Gesualdo L; Palasciano G; Johnson DW; Tonelli M; Strippoli GFM;
    J Am Soc Nephrol; 2018 Dec; 29(12):2890-2899. PubMed ID: 30420421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.
    Wu HY; Huang JW; Lin HJ; Liao WC; Peng YS; Hung KY; Wu KD; Tu YK; Chien KL
    BMJ; 2013 Oct; 347():f6008. PubMed ID: 24157497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
    Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
    Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Chen YJ; Li LJ; Tang WL; Song JY; Qiu R; Li Q; Xue H; Wright JM
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008170. PubMed ID: 30480768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.
    Vejakama P; Thakkinstian A; Lertrattananon D; Ingsathit A; Ngarmukos C; Attia J
    Diabetologia; 2012 Mar; 55(3):566-78. PubMed ID: 22189484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials.
    Hiremath S; Fergusson DA; Fergusson N; Bennett A; Knoll GA
    Am J Kidney Dis; 2017 Jan; 69(1):78-86. PubMed ID: 27712852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis.
    Cai J; Huang X; Zheng Z; Lin Q; Peng M; Shen D
    Nephrol Dial Transplant; 2018 Nov; 33(11):1968-1976. PubMed ID: 29579289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial.
    Düsing R; Sellers F
    Curr Med Res Opin; 2009 Sep; 25(9):2287-301. PubMed ID: 19635044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials.
    Bangalore S; Fakheri R; Toklu B; Messerli FH
    BMJ; 2016 Feb; 352():i438. PubMed ID: 26868137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease.
    White CM; Greene L
    J Manag Care Pharm; 2011 Jun; 17(5 Suppl):S1-15. PubMed ID: 21780334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.